Get the Stockscreener App
55.55
2.06%
1.12
After Hours:
55.55
Ultragenyx Pharmaceutical Inc stock is traded at $55.55, with a volume of 547.36K.
It is up +2.06% in the last 24 hours and down -2.17% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$54.43
Open:
$54.22
24h Volume:
547.36K
Relative Volume:
0.76
Market Cap:
$5.02B
Revenue:
$481.30M
Net Income/Loss:
$-585.12M
P/E Ratio:
-6.1929
EPS:
-8.97
Net Cash Flow:
$-492.48M
1W Performance:
-3.49%
1M Performance:
-2.17%
6M Performance:
+18.98%
1Y Performance:
+55.82%
1-Day Range:
$53.75
$56.22
1-Week Range:
$53.75
$58.14
52-Week Range:
$31.52
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Ultragenyx's SWOT analysis: rare disease biotech stock faces pivotal year - Investing.com India
Millennium Management LLC Has $76.07 Million Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
425,000 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Acquired by Frazier Life Sciences Management L.P. - MarketBeat
Axa S.A. Purchases 92,567 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Rating Reiterated by Royal Bank of Canada - MarketBeat
Fred Alger Management LLC Trims Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting - GlobeNewswire
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting - EIN News
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by First Light Asset Management LLC - MarketBeat
Seven Eight Capital LP Sells 35,796 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
UGRO Capital: Brokerages bullish on this stockCheck details - India.com
Broker’s call: UGRO Capital (Outperform) - BusinessLine
UGRO Capital Stock Jumps Ahead of Board Meeting; Know Share Price Target - Times Now
UltraTech Cement outperforms competitors on strong trading day - MarketWatch
UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock - Insider Monkey
Smallcap NBFC stock UGRO Capital surges 5% ahead of crucial board meeting; 2 brokerages predict Up to 37% upside | Stock Market News - Mint
This smallcap NBFC stock rose 5% ahead of Board meeting to raise funds - Business Standard
Massachusetts Financial Services Co. MA Has $15.22 Million Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Trading (RARE) With Integrated Risk Controls - Stock Traders Daily
XTX Topco Ltd Buys Shares of 4,012 United Therapeutics Co. (NASDAQ:UTHR) - Defense World
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views - Benzinga
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
UGRO Capital Limited (NSE:UGROCAP) Could Be Riskier Than It Looks - Simply Wall St
Cantor Fitzgerald Reaffirms "Overweight" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) - MarketBeat
Universal Health Services: Stock Has Lots Of Upside Runway (NYSE:UHS) - Seeking Alpha
Ultragenyx stock soars to 52-week high, hits $58.77 By Investing.com - Investing.com Australia
Federated Hermes Inc. Raises Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx stock soars to 52-week high, hits $58.77 - Investing.com
Ultragenyx Pharmaceutical (NASDAQ:RARE) Hits New 52-Week High at $58.88 - MarketBeat
Ultragenyx stock soars to 52-week high, hits $58.77 - Investing.com India
Ultragenyx stock soars to 52-week high, hits $58.77 By Investing.com - Investing.com UK
TD Asset Management Inc Sells 71,276 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
How To Trade (RARE) - Stock Traders Daily
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Pier 88 Investment Partners LLC - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Ultragenyx executive sells shares worth over $5,000 By Investing.com - Investing.com Australia
Ultragenyx executive sells shares worth over $5,000 - Investing.com India
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CEO Sells 20,000 Shares - MarketBeat
Ultragenyx executive sells shares worth over $5,000 - Investing.com
Ultragenyx CEO sells shares worth over $1.1 million - Investing.com
Ultragenyx CEO sells shares worth over $1.1 million By Investing.com - Investing.com UK
Ultragenyx executive sells shares worth over $5,000 By Investing.com - Investing.com UK
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now - Insider Monkey
Ultragenyx Pharmaceutical Inc. (RARE): Among the Best Mid-Cap Healthcare Stocks To Buy Now - Yahoo Finance
Bank of New York Mellon Corp Sells 129,713 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Rett Syndrome Market Expected to Experience Major Growth - openPR
10 Best Mid-Cap Healthcare Stocks To Buy Now - Insider Monkey
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Acquired by Privium Fund Management B.V. - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Increases Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx to Participate in Investor Conferences in September - GlobeNewswire
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):